Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives

• DOI: 10.1016/j.apsb.2024.02.019
• Publication Date: 2024-02-28T02:13:07Z
• Authors: Bingwen Ding; Zhu Zhu; Cong Guo; Jiaxin Li; Yong Gan; Miaorong Yu
• Keywords: Glucagon-like peptide-1; 0301 basic medicine; 0303 health sciences; Biodistribution; Diabetes; Insulin; Therapeutics. Pharmacology; RM1-950; Review; Delivery platforms; Oral peptides

Diabetes, characterized by hyperglycemia, is a major cause of death and disability worldwide. Peptides, such as insulin glucagon-like peptide-1 (GLP-1) analogs, have shown promise treatments for diabetes due to their ability mimic or enhance insulin's actions in the body. Compared subcutaneous injection, oral administration anti-diabetic peptides preferred approach. However, biological barriers significantly reduce efficacy peptide therapeutics. Recent advancements drug delivery systems formulation techniques greatly improved therapeutics treating diabetes. This review will highlight (1) benefits therapeutics; (2) delivery, including pH enzyme degradation, intestinal mucosa barrier, biodistribution barrier; (3) platforms overcome these barriers. Additionally, discuss prospects this field. The information provided serve valuable guide future developments